261![AIDS InfoNet www.aidsinfonet.org Fact Sheet Number 001A AIDS InfoNet www.aidsinfonet.org Fact Sheet Number 001A](https://www.pdfsearch.io/img/e80bd8685b5bf695aed5b1de259c51ba.jpg) | Add to Reading ListSource URL: www.aidsinfonet.orgLanguage: English - Date: 2013-09-05 09:42:15
|
---|
262![Organic chemistry / Gilead Sciences / Organofluorides / Cyclopropanes / Non-nucleoside reverse transcriptase inhibitors / Antiretroviral drug / Reverse-transcriptase inhibitor / Emtricitabine / AIDS / HIV/AIDS / Chemistry / Medicine Organic chemistry / Gilead Sciences / Organofluorides / Cyclopropanes / Non-nucleoside reverse transcriptase inhibitors / Antiretroviral drug / Reverse-transcriptase inhibitor / Emtricitabine / AIDS / HIV/AIDS / Chemistry / Medicine](/pdf-icon.png) | Add to Reading ListSource URL: www.aidsinfonet.orgLanguage: English - Date: 2013-09-05 09:42:15
|
---|
263![The United States President’s Emergency Plan for AIDS Relief Bringing Hope: Supplying Antiretroviral Drugs for HIV/AIDS Treatment The United States President’s Emergency Plan for AIDS Relief Bringing Hope: Supplying Antiretroviral Drugs for HIV/AIDS Treatment](https://www.pdfsearch.io/img/5c85d4889bdcf5a0e1331706ce60f144.jpg) | Add to Reading ListSource URL: www.state.govLanguage: English - Date: 2014-08-02 19:44:55
|
---|
264![January 5, [removed]Vol[removed]Nos. 51 &[removed]Serious Adverse Events Attributed to Nevirapine Regimens for Postexposure Prophylaxis After HIV Exposures — Worldwide, 1997–2000 January 5, [removed]Vol[removed]Nos. 51 &[removed]Serious Adverse Events Attributed to Nevirapine Regimens for Postexposure Prophylaxis After HIV Exposures — Worldwide, 1997–2000](https://www.pdfsearch.io/img/fe82b0febc821db11974440b775307b7.jpg) | Add to Reading ListSource URL: www.cdc.govLanguage: English - Date: 2001-08-06 10:02:32
|
---|
265![ADAGEN® (pegademase bovine) Injection DESCRIPTION ADAGEN® (pegademase bovine) Injection DESCRIPTION](https://www.pdfsearch.io/img/91384268d8a6f281200366c1b1b93fbe.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2014-06-10 15:35:42
|
---|
266![Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination](https://www.pdfsearch.io/img/f7ef9c3d4bf8ce4c35bf7ccd743b4961.jpg) | Add to Reading ListSource URL: www.cdc.govLanguage: English - Date: 2013-10-30 10:15:46
|
---|
267![Please note: An erratum has been published for this issue. To view the erratum, please click here. Morbidity and Mortality Weekly Report Recommendations and Reports November 22, [removed]Vol[removed]No. RR-18 Please note: An erratum has been published for this issue. To view the erratum, please click here. Morbidity and Mortality Weekly Report Recommendations and Reports November 22, [removed]Vol[removed]No. RR-18](https://www.pdfsearch.io/img/291cca763bf97a0fa4c4e5864673f44c.jpg) | Add to Reading ListSource URL: www.cdc.govLanguage: English - Date: 2002-11-27 11:42:19
|
---|
268![HIV Resistance Collaborative Group Data Analysis Plan for Resistance HIV Resistance Collaborative Group Data Analysis Plan for Resistance](https://www.pdfsearch.io/img/c1e0ab6e12e752baa4a422681b4ef66b.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English - Date: 1999-10-29 04:20:00
|
---|
269![1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EDURANT safely and effectively. See full prescribing information for EDURANT. 1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EDURANT safely and effectively. See full prescribing information for EDURANT.](https://www.pdfsearch.io/img/9076081651350bf8c87499d966ed3f99.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2011-05-20 11:23:31
|
---|
270![HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COMPLERA safely and effectively. See full prescribing information for COMPLERA. • HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COMPLERA safely and effectively. See full prescribing information for COMPLERA. •](https://www.pdfsearch.io/img/e5b23a218f741140f854b110f40eebdc.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2014-06-10 15:35:43
|
---|